Skip to content
Home/Companies/MedTech/HemoDynes
HemoDynes

HemoDynes

MedTech·France·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns HemoDynes?

HemoDynes is a French MedTech company, currently owned by 50 Partners since 2021.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
50 Partners
Investor
50 Partners
50 Partners Capital Health · 2022 · VC

Key facts

HQFrance
SectorMedTech
Websitehemodynes.com

More from 50 Partners Capital Health

Other portfolio companies in the same fund.

Ekoria
Active
FintechFrance
Ed.ai
Active
EdTechFrance· 2026
Finoptis
Active
FintechFrance· 2026
Linc
Active
HR TechFrance· 2026
Reed Material
Active
France· 2026
BioHive
Active
BiotechFrance· 2025

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns HemoDynes?

HemoDynes is currently owned by 50 Partners, through 50 Partners Capital Health, since 2021.

When did 50 Partners acquire HemoDynes?

50 Partners acquired HemoDynes in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue